1. Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Overview

5. MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole Plus Placebo

6. MONALEESA-2 Updated Results

7. MONALEESA-2: Grade 3/4 AEs

8. Additional Analyses of MONALEESA-2

9. MONALEESA-7

10. PALOMA-1: First-Line Therapy With Palbociclib

11. PALOMA-2: First-Line Therapy With Palbociclib

12. PALOMA-3: Palbociclib in Progressive Disease

13. MONARCH 1: Abemaciclib

14. MONARCH 2: Abemaciclib in Progressive Disease

15. MONARCH 3

16. MONARCH 3: Survival Data

17. MONARCH 3: Incidence of AEs

18. Differentiating Among the CDK 4/6 Inhibitors

19. Integrating the CDK 4/6 Inhibitors Into Practice

20. Management of ER+ Metastatic Breast Cancer in 2017

21. Treatment Indications for CDK 4/6 Inhibitors

22. Integrating the CDK 4/6 Inhibitors Into Practice: Unanswered Questions

23. Abbreviations

24. Abbreviations (cont)